What Helex does
Founded in 2021, Helex operates in Health Tech industry. The company focuses on non-viral targeted delivery and genome editing, utilising its proprietary kidney tropic lipid nanoparticle delivery system alongside the Epic-Cure(TM) 3D genome-based drug designer platform. Helex aims to establish a comprehensive renal franchise of precise and scalable therapeutics. Its lead asset targets Autosomal Dominant Polycystic Kidney Disease, which affects over 4 million people globally, creating a potential one-and-done therapy for this condition.
Who runs it
Funding and finances
Why this matters to you: funding stage is a rough proxy for how long the runway is and how much structure to expect. It is not a promise, and a profitable bootstrapped company can be the safer bet.
Check the company’s own careers page — linked at the top — before a job board. A role appears there first, sometimes weeks before it is syndicated anywhere else.
Questions and experiences
Nobody has asked anything about Helex yet. If you have interviewed here, what you know is worth more to the next person than anything on the rest of this page.
Company facts compiled from public sources and last refreshed 9 September 2026. Details change; treat the company’s own site as the authority.